December 14th, 2020 | 12:37 CET
BYD, Almonty Industries, Alexion - Take advantage of the correction!
Table of contents:
Clear target in sight
Unimpressed by the news of the past few days, the Canadian Company Almonty Industries is pursuing its goal of building the world's largest tungsten mine in Sangdong, South Korea. This mine would then produce 5% of the world's tungsten production and cover 30% of production outside China. The final contract with KfW-IPEX Bank was signed last week. The project financing is worth USD 75.1 million. A buyer for the tungsten concentrates, which are to be produced in Sangdong from 2022, has already been found. It is the Austrian Plansee Group, which is also providing EUR 30 million in bank guarantees to mitigate potential cost overruns.
The fact that a long, trusting partnership is emerging here is reflected in the shareholder book. The Plansee Group takes over shares from the Company's CEO, making it the main shareholder. Deutsche Rohstoff AG remains on board with a current stake of 12.8%. Analyst Simon Scholes of First Equity Research celebrates this deal with a "buy" rating. His target price is CAD 1.45. Currently, Almonty's share price is at CAD 0.66, a potential doubling opportunity!
Vaccine candidate with record acquisition
AstraZeneca is still well in the global race for approval of a vaccine against the Coronavirus. Although the British Company has been left behind in the timetable by its competitors Moderna and the joint venture between BioNtech and Pfizer, a marketing authorization application could still be submitted within the next six weeks if the results of the trials are positive. Now the British pharmaceutical giant, formed in 1999 from the merger of Sweden's Astra with Britain's Zeneca, is looking to expand its portfolio.
Record acquisition to expand
The purchase of the US biotech Company Alexion is worth a whopping USD 39.0 billion to the British Company. In the process, AstraZeneca intends to pay a total of USD 175 per Alexion share in cash as well as in its own securities. With the acquisition, AstraZeneca aims to expand its immunology and rare diseases business. In 2019, Alexion generated sales of just under USD 5.0 billion in this division. The lion's share of this is accounted for by the drug Soliris. This drug is used to treat paroxysmal nocturnal hemoglobinuria, a rare, life-threatening disease that leads to the destruction of red blood cells. Currently, the British themselves have a stock market value of EUR 115.99 billion. The expansion of the product range makes sense, and the acquisition target promises great potential. Moreover, the British are still lagging in vaccine development. However, the demand will be so great that enormous sales can still be generated upon approval.
Strong figures confirm the trend
The electric car manufacturer BYD continues to deliver strong delivery figures. In November 2020, for example, a total of 53,943 vehicles were delivered to customers, more than 6,200 more than in the previous month. The main sales driver here was, of course, the New Energy Vehicle segment, which consists primarily of hybrid and all-electric vehicles. With 26,690 units, the Chinese recorded a healthy increase of well over 200% compared with the same period last year, when only 11,220 units were sold. By contrast, sales of cars with internal combustion engines fell by 9.4%.
Share too expensive
Arguing that the stock was overvalued, analysts at asset manager UBS lowered the stock from "neutral" to "sell." The "Build your dreams" share has received some advance praise in recent months, which is reflected in the significantly increased share price. Currently, the share price, which reached its high at EUR 22.39, is going through a first correction phase. At EUR 18.20, there is a broad support zone that has already been successfully defended once. The 50-day line is now also located in this area. If this zone holds, BYD could soon head north again.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.